financetom
Business
financetom
/
Business
/
MARA Holdings Q3 Earnings: Revenue Miss; EPS Miss; 2,070 Bitcoin Mined; Energized Hash Rate Up 9%; Exahash Target 'Firmly In Sight'
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
MARA Holdings Q3 Earnings: Revenue Miss; EPS Miss; 2,070 Bitcoin Mined; Energized Hash Rate Up 9%; Exahash Target 'Firmly In Sight'
Nov 12, 2024 7:17 PM

Bitcoin (CRYPTO: BTC) miner MARA Holdings Inc ( MARA ) reported financial results for the third quarter after the close on Tuesday. Here’s a rundown of the report.

Q3 Earnings: MARA Holdings ( MARA ) reported third-quarter revenue of $131.6 million, missing the consensus estimate of $151.67 million, according to Benzinga Pro. The Bitcoin miner reported an adjusted loss of 34 cents per share, missing analyst estimates for a loss of 26 cents per share.

Total revenue was up 35% year-over-year. MARA Holdings’ energized hash rate increased 9% quarter-over-quarter to 40.2 EH/s in the third quarter. The company said it mined 2,070 Bitcoin during the quarter. The company also purchased 6,210 Bitcoin during the quarter, primarily using proceeds from a $300 million offering of convertible notes.

MARA Holdings ( MARA ) held a total of 26,747 Bitcoin at quarter’s end. The company had $1.9 billion in unrestricted cash, cash equivalents and bitcoin as of Sept. 30.

“Our 50 exahash goal for this year is firmly in sight and we expect to get there by mid-to-late December,” the company said in a letter to shareholders.

“We believe we are on a strong growth trajectory, with no plans to slow down. We anticipate continued expansion across U.S. and international markets and have set ambitious goals to expand our portfolio of owned and operated sites.”

MARA Price Action: MARA Holdings ( MARA ) shares were down 4.84% after hours trading at $24.018 at the time of publication Tuesday, per Benzinga Pro.

See Also:

Bitcoin Nears $90,000, Dogecoin Soars, Ethereum Steady — Trader Eyes $100,000 Breakout If Milestone Hits Today

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
What's Going On With Opiate Screening Tests-Focused Intelligent Bio Solutions Stock On Monday?
What's Going On With Opiate Screening Tests-Focused Intelligent Bio Solutions Stock On Monday?
Sep 9, 2024
Monday, Intelligent Bio Solutions Inc. ( INBS ) stock is trading higher with a session volume of 62.49 million compared to the average volume of 154k, as per data from Benzinga Pro. The company reported preliminary fiscal fourth-quarter 2024 revenue of $0.73 million, up 64% year-over-year compared to the consensus of $1.43 million. The fiscal year 2024 sales increased 148%...
ManpowerGroup's Staffing Unit to Open Job Hubs at US Walmart Locations
ManpowerGroup's Staffing Unit to Open Job Hubs at US Walmart Locations
Sep 9, 2024
10:25 AM EDT, 09/09/2024 (MT Newswires) -- ManpowerGroup's ( MAN ) Manpower unit said Monday it will open job hubs inside seven US Walmart (WMT) locations. The staffing firm will provide an all-in-one service for people actively looking for jobs and those casually exploring job options, the company said. The first two job hubs are set to open in Sturtevant,...
Crexendo Opens New Data Centers in Australia
Crexendo Opens New Data Centers in Australia
Sep 9, 2024
10:31 AM EDT, 09/09/2024 (MT Newswires) -- Crexendo ( CXDO ) said Monday opened new data centers Sydney and Melbourne to support its NetSapiens Platform Partners in the region and to expand worldwide. The expansion builds on the partnership with Oracle (ORCL) Cloud Infrastructure, which was announced in May, with the data centers in Australia adding to services from the...
GSK Says Depemokimab Results Show 54% Decrease in Severe Asthma Exacerbations
GSK Says Depemokimab Results Show 54% Decrease in Severe Asthma Exacerbations
Sep 9, 2024
10:24 AM EDT, 09/09/2024 (MT Newswires) -- GSK (GSK) said Monday that data from the SWIFT-1 and SWIFT-2 phase 3 trials evaluating the efficacy and safety of depemokimab compared with placebo in adults and adolescents with severe asthma showed that both trials met their primary endpoints. The data, presented at the European Respiratory Society International Conference in Austria, showed statistically...
Copyright 2023-2026 - www.financetom.com All Rights Reserved